This suggests that PRMT5 binding to R596 on Keap1 inhibits ubiquitination and degradation of Keap1, thereby down-regulating Nrf2 and expression of its downstream gene and promoting the innate resistance of cancer tissues to immunotherapy. The gene discussed is KEAP1; the disease is cancer.